Compare OFIX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | MYGN |
|---|---|---|
| Founded | 1987 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 625.5M |
| IPO Year | N/A | 1995 |
| Metric | OFIX | MYGN |
|---|---|---|
| Price | $15.15 | $6.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $21.50 | $11.82 |
| AVG Volume (30 Days) | 190.2K | ★ 874.1K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $818,058,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $3.97 | $0.08 |
| Revenue Next Year | $5.84 | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.31 | 0.21 |
| 52 Week Low | $10.24 | $3.76 |
| 52 Week High | $20.48 | $15.47 |
| Indicator | OFIX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 34.22 |
| Support Level | $14.88 | $6.38 |
| Resistance Level | $16.00 | $6.89 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 25.82 | 2.26 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.